Biopharma Life Sciences 713768651.jpg
Our Work

Latham & Watkins Advises atai Life Sciences in Strategic Investment in Beckley Psytech

January 4, 2024
A cross-border team advises the clinical-stage biopharmaceutical company in the deal to accelerate the clinical development of short-duration psychedelics.

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, has announced a strategic investment in Beckley Psytech Limited, a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.

Latham & Watkins advised atai Life Sciences in the transaction, with a corporate deal team led by New York partner Nathan Ajiashvili and London partner Emily Cridland, with London associates Samantha Peacock, Róisín Mbonu, and Venice Ma. Advice was also provided on regulatory matters by Chicago partner Laura Ferrell, with associate Daniel Filstrup; on public company representation matters by New York Counsel Irina Yevmenenko, with London associate Jason Hyatt; and on data and technology matters by London associates Sara Patel and Ami Sodha.